134 related articles for article (PubMed ID: 9071501)
1. The use of radiolabeled antibodies in bone marrow transplantation for hematologic malignancies.
Matthews DC; Appelbaum FR; Press OW; Eary JF; Bernstein ID
Cancer Treat Res; 1997; 77():121-39. PubMed ID: 9071501
[No Abstract] [Full Text] [Related]
2. Radioimmunotherapy-based conditioning regimens for stem cell transplantation.
Zhang MM; Gopal AK
Semin Hematol; 2008 Apr; 45(2):118-25. PubMed ID: 18381107
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies in the treatment of myelogenous leukemias.
Scheinberg DA
Cancer Treat Res; 1993; 64():213-32. PubMed ID: 7680876
[No Abstract] [Full Text] [Related]
4. Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Caron PC; Scheinberg DA
Leuk Lymphoma; 1993; 11 Suppl 2():1-6. PubMed ID: 8124221
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
[TBL] [Abstract][Full Text] [Related]
6. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia.
Appelbaum FR; Matthews DC; Eary JF; Badger CC; Kellogg M; Press OW; Martin PJ; Fisher DR; Nelp WB; Thomas ED
Transplantation; 1992 Nov; 54(5):829-33. PubMed ID: 1440849
[TBL] [Abstract][Full Text] [Related]
7. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
8. Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.
Swords R; Hayden PJ; Molloy K; Lawlor M; Browne PV; Murphy PT
Eur J Haematol; 2004 Dec; 73(6):450-1. PubMed ID: 15522070
[No Abstract] [Full Text] [Related]
9. [Monoclonal antibody therapies for acute leukemia].
Takeshita A; Ono R
Rinsho Ketsueki; 2002 May; 43(5):353-6. PubMed ID: 12096485
[No Abstract] [Full Text] [Related]
10. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
[TBL] [Abstract][Full Text] [Related]
11. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia.
Caron PC; Schwartz MA; Co MS; Queen C; Finn RD; Graham MC; Divgi CR; Larson SM; Scheinberg DA
Cancer; 1994 Feb; 73(3 Suppl):1049-56. PubMed ID: 8306247
[TBL] [Abstract][Full Text] [Related]
12. Half-match bone marrow transplants may raise odds for more recipients.
Hede K
J Natl Cancer Inst; 2011 May; 103(10):781-3. PubMed ID: 21551416
[No Abstract] [Full Text] [Related]
13. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.
Mejstríková E; Kalina T; Trka J; Starý J; Hrusák O
Leukemia; 2005 Jun; 19(6):1092-4. PubMed ID: 15830012
[No Abstract] [Full Text] [Related]
14. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic monoclonal antibodies in onco-hematology].
Cartron G; Rossi JF
Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
[TBL] [Abstract][Full Text] [Related]
16. [Antibody therapy for acute leukemia].
Takeshita A
Nihon Rinsho; 2007 Jan; 65 Suppl 1():408-15. PubMed ID: 17474439
[No Abstract] [Full Text] [Related]
17. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Matthews DC
Leukemia; 1998 Sep; 12 Suppl 1():S33-6. PubMed ID: 9777893
[TBL] [Abstract][Full Text] [Related]
18. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Giles FJ
Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation.
Bender JG; Unverzagt K; Walker DE; Lee W; Smith S; Williams S; Van Epps DE
Clin Immunol Immunopathol; 1994 Jan; 70(1):10-8. PubMed ID: 7505211
[TBL] [Abstract][Full Text] [Related]
20. Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia.
Robertson MJ; Roy DC; Stone RM; Ritz J
Prog Clin Biol Res; 1994; 389():47-63. PubMed ID: 7700916
[No Abstract] [Full Text] [Related]
[Next] [New Search]